DD144667A5 - Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern - Google Patents

Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern Download PDF

Info

Publication number
DD144667A5
DD144667A5 DD79213967A DD21396779A DD144667A5 DD 144667 A5 DD144667 A5 DD 144667A5 DD 79213967 A DD79213967 A DD 79213967A DD 21396779 A DD21396779 A DD 21396779A DD 144667 A5 DD144667 A5 DD 144667A5
Authority
DD
German Democratic Republic
Prior art keywords
sub
compound
general formula
och
ester
Prior art date
Application number
DD79213967A
Other languages
German (de)
English (en)
Inventor
Peder B Berntsson
Stig A I Carlsson
Jan Oe Gaarder
Bengt R Ljung
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20335348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD144667(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of DD144667A5 publication Critical patent/DD144667A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
DD79213967A 1978-06-30 1979-06-28 Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern DD144667A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7807404A SE429652B (sv) 1978-06-30 1978-06-30 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester

Publications (1)

Publication Number Publication Date
DD144667A5 true DD144667A5 (de) 1980-10-29

Family

ID=20335348

Family Applications (1)

Application Number Title Priority Date Filing Date
DD79213967A DD144667A5 (de) 1978-06-30 1979-06-28 Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern

Country Status (24)

Country Link
US (1) US4264611A (lv)
EP (1) EP0007293B1 (lv)
JP (1) JPS559083A (lv)
AT (1) ATE1237T1 (lv)
AU (1) AU529116B2 (lv)
BG (1) BG61420B2 (lv)
CA (1) CA1117530A (lv)
CS (1) CS241021B2 (lv)
CY (1) CY1299A (lv)
DD (1) DD144667A5 (lv)
DE (1) DE2963150D1 (lv)
DK (1) DK148978C (lv)
FI (1) FI70573C (lv)
HK (1) HK60585A (lv)
HU (1) HU178568B (lv)
IE (1) IE48650B1 (lv)
LU (2) LU88666I2 (lv)
NL (2) NL930054I2 (lv)
NO (3) NO151965C (lv)
NZ (1) NZ190809A (lv)
SE (1) SE429652B (lv)
SG (1) SG26085G (lv)
SU (2) SU856380A3 (lv)
ZA (1) ZA792804B (lv)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
IL68604A0 (en) * 1982-05-21 1983-09-30 Haessle Ab Processes for preparing therapeutically active dihydropyridines and intermediates for the processes
US4656181A (en) * 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
FI852359L (fi) * 1984-06-27 1985-12-28 Hoffmann La Roche Dihydropyridinderivat.
US4757071A (en) * 1984-12-14 1988-07-12 Nisshin Flour Milling Co., Ltd. 1,4-dihydropyridine derivatives, and pharmaceutical compositions containing same, useful for treating cardiovascular diseases
DE3447169A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Optisch aktive nitrodihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4920225A (en) * 1986-12-22 1990-04-24 Laboratoires Syntex S.A. Resolution of 1,4-dihydropyridine derivatives
JPS63255071A (ja) * 1987-04-14 1988-10-21 株式会社　岡田吾作郎商店 磁石内蔵健康棒
AT391269B (de) * 1988-12-30 1990-09-10 Burghart Kurt Pharmazeutische zubereitung
US5310917A (en) * 1991-09-13 1994-05-10 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropydrines
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
JPH07501551A (ja) * 1991-12-02 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋なｓ（−）フェロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
EP0657432B1 (de) 1993-12-10 2003-03-12 Bayer Ag Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität
DE4430639A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5977369A (en) * 1995-12-28 1999-11-02 Napp Technologies, Inc. Process to prepare dihydropyridine and derivatives thereof
SE9600086D0 (sv) * 1996-01-10 1996-01-10 Astra Ab New manufacturing process
IT1283793B1 (it) * 1996-08-23 1998-04-30 Lusochimica Spa Processo per la preparazione di diidropiridine
WO2000005209A1 (en) * 1998-07-23 2000-02-03 Lin, Tong-Ho GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
EP1285655B1 (en) * 2000-04-11 2007-05-30 Sankyo Company, Limited Stabilized pharmaceutical compositions containing the calcium channel blocker azelnidipine
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
GEP20084406B (en) * 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
CN102827068A (zh) * 2011-06-17 2012-12-19 张锐豪 一种4-(2, 3-二氯苯基)-2, 6-二甲基-1, 4-二氢-5-甲氧基羰基-3-吡啶羧酸的制备方法
MX2014002163A (es) 2011-08-26 2014-09-25 Wockhardt Ltd Métodos para el tratamiento de desórdenes cardiovasculares.
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN104177286A (zh) * 2014-08-11 2014-12-03 广东东阳光药业有限公司 一种地平类药物的制备方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR101824982B1 (ko) 2015-10-07 2018-02-02 엘지전자 주식회사 차량 및 그 제어방법
CN107952483B (zh) * 2017-12-18 2020-07-28 万华化学集团股份有限公司 一种催化剂，使用该催化剂的反应器，以及一种制备β-苯乙醇的方法
CN108840819B (zh) * 2018-04-02 2021-07-30 常州瑞明药业有限公司 一种非洛地平的制备方法
CA3103616A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
DE1670824C3 (de) * 1967-03-20 1978-08-03 Bayer Ag, 5090 Leverkusen 1,4-Dihydropyridin-33-dicarbonsäurealkylester
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117573C3 (de) * 1971-04-10 1978-07-27 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von unsymmetrischen l,4-Dihydropyridin-3,5dicarbonsäureestern, sowie ihre Verwendung als Arzneimittel
DE2210672C3 (de) * 1972-03-06 1980-03-20 Bayer Ag, 5090 Leverkusen N-substituierte unsymmetrische 1 ^-Dihydropyridin-S^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof

Also Published As

Publication number Publication date
LU88306I2 (fr) 1994-05-04
NO151965B (no) 1985-04-01
NO792112L (no) 1980-01-03
US4264611B1 (lv) 1984-07-17
DK148978C (da) 1986-08-18
FI70573C (fi) 1986-09-24
EP0007293B1 (en) 1982-06-23
DE2963150D1 (en) 1982-08-12
US4264611A (en) 1981-04-28
NL940012I1 (nl) 1994-08-01
HK60585A (en) 1985-08-23
IE48650B1 (en) 1985-04-03
CS241021B2 (en) 1986-03-13
SE429652B (sv) 1983-09-19
CY1299A (en) 1985-10-18
SE7807404L (sv) 1979-12-31
HU178568B (en) 1982-05-28
NL930054I2 (nl) 1994-02-16
NO151965C (no) 1985-07-10
FI792058A (fi) 1979-12-31
CA1117530A (en) 1982-02-02
SG26085G (en) 1986-01-24
NL930054I1 (nl) 1993-09-01
EP0007293A1 (en) 1980-01-23
IE791217L (en) 1979-12-30
ZA792804B (en) 1980-06-25
LU88666I2 (fr) 1996-02-01
NZ190809A (en) 1982-03-09
JPS559083A (en) 1980-01-22
ATE1237T1 (de) 1982-07-15
NO1994026I1 (no) 1994-12-21
FI70573B (fi) 1986-06-06
AU529116B2 (en) 1983-05-26
DK275079A (da) 1979-12-31
JPS6121550B2 (lv) 1986-05-27
SU856380A3 (ru) 1981-08-15
BG61420B2 (bg) 1997-07-31
DK148978B (da) 1985-12-09
NO1996006I1 (no) 1996-06-24
SU915799A3 (en) 1982-03-23
AU4831679A (en) 1980-02-07

Similar Documents

Publication Publication Date Title
DD144667A5 (de) Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern
DE69831869T2 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
DE3877492T2 (de) Pharmazeutisches praeparat mit verzoegerter abgabe eines dihydropyridins und eines beta-adrenorezeptor-antagonisten und herstellungsverfahren dessen.
DE2445584C3 (de) L- bzw. DL-2-Methyl-3- (3', 4'-dihydroxyphenyl)-alanin-ester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CH648484A5 (de) Pharmazeutische zubereitung eines festen medikamentmaterials.
EP0702953A2 (de) Darreichungsformen enthaltend Thioctsäure, oder feste Salze von Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
AT5874U1 (de) Pharmazeutische zubereitungen enthaltend amlodipinmaleat
DE1106454B (de) UEberzugsmittel fuer Arzneistoffe
DD155519A5 (de) Verfahren zur herstellung von 2-methyl-4-(2,3-dichlorphenyl)-1,4-dihydropyridin-3,5-dicarbonsaeure-3,5-diestern
DE3212736A1 (de) Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung
DE4423177A1 (de) Antihyperglykämisch wirksame Arzneimittel
EP0164588A2 (de) Dihydropyridinpräparate und Verfahren zu ihrer Herstellung
EP0163984A2 (de) Dihydropyridinkombinationspräparate und Verfahren zu ihrer Herstellung
DE3542794A1 (de) Antihypertensives kombinationspraeparat
DE3586817T2 (de) 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3787319T2 (de) 1,4-Dihydropyridin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
EP0081748A2 (de) Verfahren zur Herstellung von (-)-2-(1-(2,6-Dichlorphenoxy)-ethyl)-1,3-diazacyclopent-2-en
DE3830749A1 (de) Arzneimittel in form von kuegelchen mit hohem arzneistoffgehalt und verfahren zu ihrer herstellung
DD209816A5 (de) Verfahren zur herstellung von dihydropyridinen
DE3736866A1 (de) Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DD208614A5 (de) Verfahren zur herstellung von dihydropyridinen
DE2707763A1 (de) Verwendung von vincamin zur behandlung von kreislauferkrankungen des gehirns und dazu geeignetes arzneimittel
WO1993024130A1 (de) (-)-metrifonat enthaltendes arzneimittel
DE2738131A1 (de) Aminoketone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
CH636337A5 (en) Process for preparing novel amines having beta receptor-inhibiting activity